BioHarvest Sciences Announces that VINIA is Now the No.1 Resveratrol Polyphenol Brand in the United States

Rhea-AI Summary

BioHarvest Sciences (NASDAQ: BHST) announced that VINIA is the No.1 Resveratrol Polyphenol nutraceutical brand in the United States as of March 26, 2026.

Key metrics: U.S. revenue > $30 million in 2025, $85 million global cumulative revenue to date, ~85,000 active users, and VINIA.com accounts for ~80% of U.S. VINIA revenue. The company cites Botanical Synthesis technology that preserves plant-cell structure and magnifies piceid resveratrol up to 100x. The #1 ranking is based on NIQ 2025 market projections and Amazon sales estimates.

Positive

• Achieved #1 U.S. Resveratrol Polyphenol brand
• U.S. revenue of $30 million for full-year 2025
• Global cumulative revenue of $85 million
• 85,000 active VINIA users across U.S. and Israel
• VINIA.com drives ~80% of U.S. VINIA revenue
• Botanical Synthesis increases piceid resveratrol up to 100x

Negative

• High revenue concentration: ~80% of U.S. sales via VINIA.com
• Market leadership based on NIQ and Amazon projections, not audited retail consensus

Key Figures

U.S. VINIA revenue: more than $30 million Global VINIA revenue: approximately $85 million VINIA.com share: approximately 80% +5 more

8 metrics

U.S. VINIA revenue more than $30 million Full-year 2025 VINIA revenue in the United States

Global VINIA revenue approximately $85 million Global cumulative VINIA revenue to date

VINIA.com share approximately 80% Portion of VINIA U.S. revenue from VINIA.com website

Active VINIA users more than 85,000 Active VINIA wellness product users in U.S. and Israel

Physician patients on VINIA over 200 patients Patients consistently taking VINIA for more than a year

Piceid resveratrol magnification up to 100x Increase vs naturally found levels in red grapes

Time to U.S. leadership less than five years Time from U.S. market entry to category leadership

Category position #1 Resveratrol Polyphenol Brand Based on 2025 VINIA U.S. sales vs NIQ and Amazon projections

Market Reality Check

Price: $4.44 Vol: Volume 3,117 is low versu...

low vol

$4.44 Last Close

Volume Volume 3,117 is low versus 20-day average of 17,302 (volume_relative 0.18). low

Technical Price at 4.4449 trades below 200-day MA 7.06, about 65.27% under 52-week high and 8.41% above 52-week low.

Peers on Argus

BHST showed a modest 0.69% pre-news gain with low volume, while peers were mixed...

1 Up

BHST showed a modest 0.69% pre-news gain with low volume, while peers were mixed: ABVE up 0.6%, FTLF up 1.74%, LFVN down 4.67%, DDC down 1.95%, HAIN down 7.8%. No broad, same-direction sector move is evident.

Historical Context

5 past events · Latest: 2026-03-17 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
2026-03-17	Earnings timing	Neutral	-4.6%	Announced date and call details for Q4 and full-year 2025 results.
2026-03-05	Board transition	Neutral	-3.7%	Director resignation and appointment of Prof. Hezi Levy to board.
2026-03-03	Conference participation	Neutral	-2.4%	Participation in Roth Conference and update on funding and customers.
2026-01-07	Year-end update	Positive	+3.7%	Reported >US$36M run rate, >60% margins, 85k+ users and financing.
2025-12-18	Grant funding	Positive	+1.1%	$1.6M IIA grant to advance second-generation Botanical Synthesis platform.

Pattern Detected

Recent news (board, conferences, earnings date) often saw mild negative reactions, while more substantive business updates like grants and year-end letters aligned with positive price moves.

Recent Company History

Over the past few months, BioHarvest has focused on communicating its growth trajectory and governance evolution. A year-end letter highlighted an annualized revenue run rate above US$36 million, gross margins over 60%, and >85,000 VINIA users, with a positive price reaction. An Israeli Innovation Authority grant of $1.6 million and financing that raised about $30.8 million reinforced its balance sheet. In contrast, neutral items like board transitions, conference participation, and the upcoming Q4/FY25 earnings date saw modest share price declines, underscoring investor sensitivity to catalysts with direct financial impact.

Market Pulse Summary

This announcement underscores VINIA’s emergence as a key asset, with U.S. 2025 revenue above $30 mil...

Analysis

This announcement underscores VINIA’s emergence as a key asset, with U.S. 2025 revenue above $30 million, global cumulative revenue near $85 million, and more than 85,000 active users. It highlights BioHarvest’s Botanical Synthesis platform and a differentiated delivery system that magnifies piceid resveratrol levels by up to 100x. In context of earlier updates on strong gross margins and non-dilutive funding, investors may watch upcoming Q4/FY25 results and continued user growth to gauge how this brand leadership translates into sustained financial performance.

Key Terms

resveratrol, polyphenol, nutraceutical, bioavailability, +2 more

6 terms

resveratrol medical

"No.1 Resveratrol Polyphenol Nutraceutical Brand in the United States"

A naturally occurring plant compound found in grapes, berries and some nuts, resveratrol is often studied for potential health effects such as heart and cellular protection. Investors watch it because positive research or regulatory approvals can boost demand for supplements, attract biotech or pharmaceutical development, and affect companies that sell health products — think of it as a small ingredient that can change the value of whole product lines if proven effective.

polyphenol medical

"No.1 Resveratrol Polyphenol Nutraceutical Brand in the United States"

Polyphenols are natural compounds found in plants—such as fruits, tea, cocoa and herbs—that often act like mild protectors or preservatives for the plant and can have antioxidant effects in humans. Investors care because these compounds drive consumer demand, product differentiation, and health-related claims in food, beverage, supplement and drug markets; their presence can affect ingredient sourcing, regulatory scrutiny and the perceived value of products much like a recognizable quality label.

nutraceutical medical

"Resveratrol Polyphenol Nutraceutical Brand in the United States"

A nutraceutical is a product made from food ingredients that is promoted to provide health benefits beyond basic nutrition — for example vitamins, herbal extracts, fortified foods, and dietary supplements. Investors watch nutraceuticals because they sit between food and medicine: consumer demand, limited regulation, and claims about health effects can drive fast sales and higher margins but also create liability, regulatory risk, and uncertainty about long‑term efficacy, which affect company value.

bioavailability medical

"impressive solubility, bioavailability and efficacy qualities given the unique structure"

Bioavailability is the measure of how much and how quickly a substance, such as a medication or nutrient, enters the bloodstream and becomes available for use by the body. For investors, it matters because it influences how effectively a product works and how quickly results are seen, which can impact a company's success and the potential value of related investments. Think of it like how much of a medicine actually reaches your bloodstream after taking it—that determines how well it can do its job.

non-GMO technical

"delivers a naturally derived, patentable, non-GMO composition that preserves"

Non-GMO means a product or ingredient was produced without genetic modification techniques — the plant or organism’s DNA has not been intentionally altered in a laboratory. Investors care because non-GMO labeling can affect consumer demand, price premiums, shelf access and supply-chain cost; think of it like an organic or “no added hormones” label that can open certain markets, change margins, and create reputational risk or advantage for companies.

vasodilation medical

"Due to VINIA's vasodilation benefits and ability to improve blood flow"

Vasodilation is the widening of blood vessels, which lets blood flow more easily and typically lowers blood pressure; think of it like opening extra lanes on a highway so traffic moves faster. For investors, vasodilation matters because drugs or medical devices that cause or prevent it can determine a therapy’s usefulness, side-effect profile, regulatory approval prospects and market demand, influencing a company’s clinical success and revenue potential.

AI-generated analysis. Not financial advice.

VINIA's leadership position in the market validates its superior arterial dilation and blood flow performance as well as BioHarvest's Botanical Synthesis platform technology

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 26, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ platform, today announced that its VINIA^® brand has achieved the position of the #1 Resveratrol Polyphenol Nutraceutical Brand in the United States*.

VINIA's leadership position is driven by its clinically demonstrated ability to increase arterial dilation, improving blood flow and enabling enhanced delivery of oxygen and nutrients throughout the body. This mechanism of action addresses what many medical experts increasingly recognize as one of the most foundational elements of human health and performance: efficient blood flow and oxygen delivery.

"Achieving the No.1 position in the U.S. resveratrol category in less than five years reflects both the strength of VINIA and the power of our Botanical Synthesis platform technology," said Ilan Sobel, Chief Executive Officer of BioHarvest Sciences. "VINIA's clinically demonstrated ability to increase arterial dilation, providing blood flow benefits, combined with its unique protected plant-cell delivery system, create a differentiated product that consumers are increasingly recognizing and adopting. The strength of VINIA as a subscription base product has enabled us to build unique and credible e-commerce platform capabilities with our VINIA.com website which accounts for approximately 80% of VINIA US revenue."

VINIA's leading position in the market reflects the continued growth of the Company's direct-to-consumer business, which generated more than $30 million in U.S. revenue for full-year 2025 and approximately $85 million in global cumulative revenue to date. Less than five years after entering the U.S. market, VINIA has achieved category leadership, with more than 85,000 active users of VINIA wellness products across the United States and Israel.

Dr. Edward Maristany, member of the BioHarvest Scientific Advisory Board and Functional Medicine Physician, commented "VINIA is a life-changing compound — which has impressive solubility, bioavailability and efficacy qualities given the unique structure of the compound and the protective cell envelope which also shields the compound from degradation as it moves through our body. I have over 200 patients who have consistently taken VINIA for more than a year. The improvements in their quality of life derived from VINIA's clinically proven ability to increase arterial dilation have been significant. The effects of improved blood flow have been substantial in driving improvements in my patients' physical energy and mental alertness."

Botanical Synthesis- The Technology Behind the VINIA Brand

VINIA is built around a proprietary red grape composition featuring piceid resveratrol as its hero molecule, combined with a complex of naturally occurring grape polyphenols including catechin, quercetin, anthocyanins, and tannins. These molecules work synergistically to support arterial function and vascular performance.

The effectiveness of this composition is further enhanced by BioHarvest's proprietary Botanical Synthesis technology, which preserves the molecules inside their natural plant cell environment. This protective cell envelope safeguards the phytonutrients from degradation during production through to ingestion as well as during passage through the stomach's acidic environment, helping preserve efficacy.

Unlike traditional plant extracts that isolate individual molecules, Botanical Synthesis delivers a naturally derived, patentable, non-GMO composition that preserves the original molecular conformation of phytonutrients within their native cellular environment — creating a differentiated delivery system for plant-based compounds.

With VINIA, BioHarvest's Botanical Synthesis platform magnifies the piceid resveratrol levels by up to 100x compared to what is naturally found in red grapes, while maintaining the synergy of the full polyphenol complex.

Due to VINIA's vasodilation benefits and ability to improve blood flow, the Company views VINIA as a foundational compound to be added to other synergistic molecules to create innovative and effective nutraceutical products, further strengthening BioHarvest's leadership in plant-based health solutions.

*This #1 Resveratrol Polyphenol brand position is based on comparing VINIA® 2025 annual sales revenue in the US with the estimated market size for Resveratrol Nutritional Supplements, utilizing NielsonIQ (NIQ) 2025 market projections for Resveratrol Nutritional Supplements and Beverages, together with Amazon sales data projections for Resveratrol Nutritional Supplements, which represent the large majority of the Total Resveratrol Polyphenol Only Market.

About BioHarvest Sciences Inc.

BioHarvest (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. Launching new products is not certain, may take significant time, and is subject to risks and uncertainties beyond company control such as consumer preferences, competition landscape, government approvals required for sale or import, acceptance of benefit claims, and marketing budgets of the company and its competitors. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
(604) 622-1186
info@bioharvest.com

Investor Relations Contact:
Chuck Padala, Managing Director
LifeSci Advisors

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290040

FAQ

How did BioHarvest (BHST) determine VINIA is the No.1 resveratrol brand in the U.S. on March 26, 2026?

The company says the ranking compares VINIA 2025 U.S. sales with NIQ 2025 market projections and Amazon sales estimates. According to the company, this method uses NIQ projections plus Amazon data representing the majority of the resveratrol-only market.

What were VINIA's reported U.S. and global revenues for 2025 and to date for BHST?

According to the company, VINIA generated over $30 million in U.S. revenue for full-year 2025 and about $85 million in global cumulative revenue to date. Those figures were presented as key commercial milestones.

What percentage of VINIA U.S. revenue comes from VINIA.com and subscriptions for BHST?

According to the company, roughly 80% of VINIA U.S. revenue is driven by VINIA.com, reflecting a subscription-led direct-to-consumer model. The company attributes this to a strong e-commerce and subscription base.

How many active VINIA users did BioHarvest report as of March 26, 2026?

The company reported approximately 85,000 active users of VINIA wellness products across the United States and Israel. According to the company, this user base contributed to rapid U.S. category adoption in under five years.

What is Botanical Synthesis and how does it affect VINIA's resveratrol levels according to BHST?

According to the company, Botanical Synthesis preserves phytonutrients inside plant cells, protecting them through production and digestion. The company states this process magnifies piceid resveratrol levels by up to 100x compared to red grapes.

What clinical benefit does VINIA claim that supports its market position for BHST?

According to the company, VINIA has clinically demonstrated increases in arterial dilation and improved blood flow. The company links these vascular benefits to enhanced delivery of oxygen and nutrients and improved physical energy and alertness.